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Background: Primary plasma cell leukemia (pPCL) and
multiply-refractory multiple myeloma (MM) are plasma cell
dyscrasias with a median survival of <1 year without
aggressive treatment. Prolonged remission can be achieved
following allogeneic hematopoietic cell transplantation
(alloHCT) in this population, although survival may be
compromised by treatment-related mortality (TRM). With
the intention of providing long-term disease control, we
have offered a myeloablative conditioning regimen con-
taining melphalan 100 mg/m2 and 9 Gy of total body irra-
diation (MEL100/TBI9) followed by alloHCT to patients with
these diseases.
Methods: Seven patients with pPCL and 2 patients with
multiply-refractory MM underwent MEL100/TBI9 alloHCT at
the University of Pennsylvania between June 2009 and
January 2013. MEL was given as a single infusion of 100 mg/
m2 on day -3 and TBI as 150 cGy twice daily on days -2, -1
and 0. Paliferminwas given on days -4 (60 mg/kg) and 0 (180
mg/kg) for prevention of mucositis. Methotrexate and
tacrolimus were used for graft-versus-host-disease (GVHD)
prophylaxis. Therapies pre- and post-alloHCT were given at
the discretion of the treating physician.
Results: The median number of therapies pre- alloHCT was
3.5 (range 1-10) including bortezomib in 7 patients and high-
dose melphalan in 2 patients. Karnofsky Performance Status
pre- alloHCT was <80 in 4 patients. The median age at
alloHCT was 48 years (range 42-57). The donor source was aFigure I. EFS and OS based on disease respHLA-matched sibling in 5 patients and a 10/10 HLA-matched
unrelated donor in 4 patients. Disease response pre- alloHCT
was very good partial response (VGPR) or better for 4 pa-
tients, partial response (PR) for 3 patients and stable disease/
progressive disease (SD/PD) for 2 patients. Lenalidomide
maintenance was given post-alloHCT to 3 patients. Acute
GVHD of the intestine (3 patients; grade II, III and unknown)
and skin (1 patient; grade II) as well as chronic GVHD of the
oral cavity (2 patients; mild, moderate), skin (1 patient;
moderate) and eyes (1 patient; moderate) was observed.
With a median length of follow-up of 31.6 months post-
alloHCT (range 6.7-49.9) for patients surviving >100 days
(n¼6), the median event-free survival (EFS) was 28.2 months
and the median overall survival (OS) was not yet reached. As
shown in Figure I, patients achieving VGPR or better prior to
alloHCT experienced prolonged EFS and OS. TRM was expe-
rienced by 3 patients (2 with SD/PD and 1 with PR pre-
alloHCT), with all deaths occurring within approximately 30
days post-alloHCT due to sepsis.
Conclusions: In pPCL and multiply-refractory MM patients
demonstrating response to prior therapy, consolidation with
MEL100/TBI9 alloHCT can result in long-term survival
without severe toxicity. MEL100/TBI9 should be analyzed
prospectively either alone or in comparison to alternative
alloHCT conditioning regimens in this patient population.366
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Allogeneic hematopoietic cell transplantation (allo-HCT) can
be curative in many patients with intermediate and high risk
AML. However, patients with AMLwho relapse post allo-HCT
typically have a dismal prognosis with limited therapeutic
options. The activity and minimal toxicity associated with
hypomethylating agents (hypomeths) makes them poten-
tially useful in the management of post allo-HCT relapsed
AML patients. However, their use in this setting has not beenonse prior to MEL 100/TBI9 alloHCT
